OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
301617$66.3655

Shandong Boyuan Pharmaceutical & Chemical Co Ltd

PharmaceuticalsVerified

The company maintains a strong liquidity position with a current ratio of 6.71, indicating a robust ability to meet short-term obligations. However, its operating cash flow is negative at -2.97 million CNY, which may raise concerns about its ability to sustain operations without external financing. The price-to-book ratio of 5.13 suggests that the company is trading at a premium relative to its book value, potentially reflecting investor optimism about its future earnings potential. In terms of profitability, the company's return on equity (ROE) is 9.97%, which is a measure of how effectively it generates profit from shareholders' equity. This ROE is in line with the typical metrics for the pharmaceutical industry, though specific comparisons to cohort medians are not available in the provided data. The return on assets (ROA) of 8.93% indicates that the company is efficiently using its assets to generate earnings. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is based in China, and its exposure is primarily domestic, with no significant international operations disclosed. Looking at the growth trajectory, the company's revenue for the latest period is 1.46 billion CNY. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of -85.097 million CNY suggests a focus on cost management or asset reduction rather than expansion. The company faces a medium liquidity risk due to its negative operating cash flow, despite a strong current ratio. The risk assessment also notes that net cash is negative after subtracting total debt, which could indicate potential liquidity constraints. The dilution risk is assessed as low, with no immediate pressure for share issuance or dilution. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests a stable operational environment without major disruptions.

30-day price · 301617(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyShandong Boyuan Pharmaceutical & Chemical Co Ltd
Ticker301617.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Shandong Boyuan Pharmaceutical & Chemical Co Ltd is a pharmaceutical company that generates revenue primarily through the production and sale of pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

The company maintains a strong liquidity position with a current ratio of 6.71, indicating a robust ability to meet short-term obligations. However, its operating cash flow is negative at -2.97 million CNY, which may raise concerns about its ability to sustain operations without external financing. The price-to-book ratio of 5.13 suggests that the company is trading at a premium relative to its book value, potentially reflecting investor optimism about its future earnings potential. In terms of profitability, the company's return on equity (ROE) is 9.97%, which is a measure of how effectively it generates profit from shareholders' equity. This ROE is in line with the typical metrics for the pharmaceutical industry, though specific comparisons to cohort medians are not available in the provided data. The return on assets (ROA) of 8.93% indicates that the company is efficiently using its assets to generate earnings. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is based in China, and its exposure is primarily domestic, with no significant international operations disclosed. Looking at the growth trajectory, the company's revenue for the latest period is 1.46 billion CNY. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of -85.097 million CNY suggests a focus on cost management or asset reduction rather than expansion. The company faces a medium liquidity risk due to its negative operating cash flow, despite a strong current ratio. The risk assessment also notes that net cash is negative after subtracting total debt, which could indicate potential liquidity constraints. The dilution risk is assessed as low, with no immediate pressure for share issuance or dilution. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests a stable operational environment without major disruptions.
Key takeaways
  • The company has a strong current ratio of 6.71, indicating good short-term liquidity.
  • The negative operating cash flow of -2.97 million CNY raises concerns about the company's ability to sustain operations without external financing.
  • The company's ROE of 9.97% and ROA of 8.93% suggest efficient use of equity and assets to generate profit.
  • The company's revenue is concentrated in a single business segment, with no significant international operations disclosed.
  • The company's capital expenditure of -85.097 million CNY indicates a focus on cost management or asset reduction rather than expansion.
  • The company faces a medium liquidity risk due to its negative operating cash flow, despite a strong current ratio.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.46B
Gross profit$295.6M
Operating income$196.1M
Net income$172.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$3.0M
CapEx-$85.1M
Free cash flow$33.8M
Total assets$1.93B
Total liabilities$200.4M
Total equity$1.73B
Cash & equivalents
Long-term debt$44.2M
Valuation
Market price$66.36
Market cap$8.87B
Enterprise value$8.91B
P/E51.5
Reported non-GAAP P/E
EV/Revenue6.1
EV/Op income45.5
EV/OCF
P/B5.1
P/Tangible book5.1
Tangible book$1.73B
Net cash-$44.2M
Current ratio6.7
Debt/Equity0.0
ROA8.9%
ROE10.0%
Cash conversion-2.0%
CapEx/Revenue-5.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric301617Activity
Op margin13.4%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin11.8%14.7% medp25 11.7% · p75 28.1%below median
Gross margin20.2%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-5.8%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity3.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-22 02:11 UTCJob: f6cfdf5c